[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@stock_logging Avatar @stock_logging Stock.Logging

Stock.Logging posts on X about eps, $camx, $camxst, $krys the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence countries XXXX% travel destinations XXXX% currencies XXXX% stocks XXXX% cryptocurrencies XXXX% finance XXXX%

Social topic influence eps 8.33%, $camx 8.33%, $camxst 8.33%, $krys 8.33%, india 4.17%, japan 4.17%, currency 4.17%, stockholm 4.17%, crmd 4.17%, $crmd XXXX%

Top accounts mentioned or mentioned by @oddhootcapital @marcalcarbo @realyuvaraj @themapreducer @exclamotite69 @sycapital @topsecretstocks @szewinvest @joinyellowbrick @mufasa_capital @sy_capital

Top assets mentioned Krystal Biotech, Inc. Common Stock (KRYS) NuCypher (NU) MercadoLibre Inc (MELI) Interlay (INTR) AST SpaceMobile, Inc. Class A Common Stock (ASTS) Sezzle Inc. Common Stock (SEZL) Pagaya Technologies Ltd. Class A Ordinary Shares (PGY) Upstart Holdings, Inc. Common stock (UPST) Hundred Million (100M)

Top Social Posts #

Top posts by engagements in the last XX hours

"$CAMX.ST $CAMX Strong quarterly results from Camurus (part of my biotech basket): ➡ Revenue: SEK 675.5m +51.8% YoY (vs. SEK 653m est.) ➡ Operating profit: SEK 292.05m (43.2% margin) +253.5% YoY ➡ EPS: SEK XXXX +226.4% YoY (vs. SEK XXXX est.) Unchallenged market leader in opioid addiction treatment strong pipeline resubmission for CAM2029 (acromegaly treatment) in the U.S. expected in Q3/25 a recently announced long-term collaboration with Eli Lilly ($LLY) on its proprietary FluidCrystal technology incredible operating leverage lots to like here. In my view one of the best high-growth stocks"
@stock_logging Avatar @stock_logging on X 2025-07-17 09:00:25 UTC XXX followers, 1226 engagements

"@MarcalCarbo Absolutely Great thing about X is that so many people share their high-quality research for free really helps clear up misconceptions like this"
@stock_logging Avatar @stock_logging on X 2025-07-18 13:42:11 UTC XXX followers, XX engagements

"The company operates X segments: Ad Platform: Programmatic advertising platform in Japan with an SSP (publishers / websites monetize ad inventory) a DSP (advertisers/agencies buy ad slots) plus add-on services like publisher support. Cash cow growing 1015% p.a. Overseas Business: Programmatic advertising outside Japan (SEA India U.S.) acquired in 2023 now consolidated under Ad Platform. Digital PR: Acquired in 2024 connects influencers and content creators with brands for marketing campaigns. Marketing SaaS the crown jewel: XX% revenue CAGR since 2021 rising ARPU XXX% churn/quarter. Already"
@stock_logging Avatar @stock_logging on X 2025-07-16 12:35:26 UTC XXX followers, XXX engagements

"@sy_capital Yes indeed was down almost XX% this morning in Stockholm (I'm on vacation today so lots of time to check stock tickers 😂). Price has recovered meanwhile. Agreed really good numbers. And that despite a currency headwind of XX % 🤯"
@stock_logging Avatar @stock_logging on X 2025-07-17 10:11:22 UTC XXX followers, XX engagements

"$KRYS Strong study results for Krystal Biotech and its subsidiary Jeune Aesthetics In a randomized double-blind and placebo-controlled Phase X study pipeline candidate KB301 showed significant improvements in severe wrinkles in the dcollet area over XX months as assessed by both investigators (left column) and patients themselves (right column). Important: There is currently no FDA-approved injectable treatment for the dcollet area. Investing in $KRYS therefore not only gives exposure to the market leader in the treatment of dystrophic epidermolysis bullosa (DEB) a rare skin disease but also"
@stock_logging Avatar @stock_logging on X 2025-07-24 14:11:33 UTC XXX followers, XXX engagements

"$CRMD Ive already increased my Cormedix position by XX% this month and Im considering adding more as the valuation keeps getting cheaper. Below is a simple projection I put together. Feedback appreciated Business model in one sentence (for those unfamiliar with the stock): CorMedix sells DefenCath a catheter lock solution that prevents infections in dialysis patients. Additional indications include TPN (Total Parenteral Nutrition) and oncology. Dialysis: TAM: 37m vials (inpatient) + 3.8m vials (outpatient) = 40.8m vials total (source: company presentation). Price per vial: currently $XXX but"
@stock_logging Avatar @stock_logging on X 2025-07-19 13:24:31 UTC XXX followers, 4955 engagements

"Portfolio Update June 2025 📊 Performance YTD (measured as TTWROR in EUR): XXXXX % (converted to USD it would be about XX% higher) ➡ Holdings: $INT.ST $INT $SLYG.DE $SLYG $NXSN.TA $NXSN $NU $MELI $7378.T $INTR $ALSTI $ALSTI.PA $247A.T $KURN.SW $KURN $ASTS $5621.T $SOFW.TA $SOFW $4374.T $5134.T $HROW $CAMX.ST $CAMX $4377.T $KRYS $4493.T $277A.T $215A.T $CRMD $4475.T $9911.HK $ALLIX $ALLIX.PA $4419.T $ETON ➕ New positions $CAMX.ST $KURN.SW $215A.T $CRMD $WALLIX.PA $9911.HK 🔼 Increased positions $KRYS $NU $HROW $ETON $4419.T ❌ Exited positions $OPTIMA.AT $TMDX $TBCG.L $4058.T $ASPI 🔻 Trimmed"
@stock_logging Avatar @stock_logging on X 2025-07-01 15:10:43 UTC XXX followers, 24.1K engagements

"$SEZL I always had Sezzle in my shitco / bad business model bucket but this write-up completely changed my view. Brilliantly written and I can highly recommend giving it a read On my WL now"
@stock_logging Avatar @stock_logging on X 2025-07-18 13:38:29 UTC XXX followers, 1824 engagements

"@topsecretstocks Interesting pitch Does Pagaya $PGY like Upstart $UPST also hold loans on its own balance sheet or do they carry no credit risk at all"
@stock_logging Avatar @stock_logging on X 2025-07-22 18:34:07 UTC XXX followers, XXX engagements

"@RealYuvaraj Yes I assumed $100m in TPN sales by 2029. Im aware that 2027 is the planned launch year so sales by 2029 could of course be lower maybe closer to $50m. But even in that case the stock would still be undervalued"
@stock_logging Avatar @stock_logging on X 2025-07-20 05:15:49 UTC XXX followers, XXX engagements